Ensuring adequate nutrition is one of the cornerstones of management in children with chronic kidney disease (CKD). Poor nutrition is not only a prime aetiology of delayed growth and short stature but also exacerbates the fluid and electrolyte abnormalities already present in children with CKD \[[@sfy008-B1]\]. Impaired growth is associated with increased morbidity and mortality both as a child and into adulthood, including the psychological implications to the child of being smaller than his/her peers, increased school absenteeism and more frequent hospital admissions \[[@sfy008-B1]\]. Several other important complications of CKD may be exacerbated by poor nutrition, including but not limited to electrolyte disturbances (most notably hyperkalaemia), poorer bone health (secondary to calcium and phosphate imbalance) and anaemia \[[@sfy008-B1], [@sfy008-B2]\]. Dietary restrictions are used to address many of these issues. However, maintaining adequate nutrition and managing often suboptimal poor patient/family concordance with these restrictions remains challenging.

In the context of hyperkalaemia, simple dietary restriction is often inadequate to maintain serum potassium within an acceptable range. Ion exchange resins are commonly used as an adjunctive therapy. Sodium polystyrene sulphonate (SPS), a commonly available exchange resin, can be administered either orally or rectally \[[@sfy008-B3]\]. However, the reported adverse effect profile includes potentially fatal gastrointestinal side effects such as intestinal necrosis \[[@sfy008-B3]\], aspiration pneumonitis \[[@sfy008-B6], [@sfy008-B7]\], metabolic alkalosis with subsequent seizures \[[@sfy008-B3], [@sfy008-B8]\], palatability \[[@sfy008-B9]\] and blockage of feeding routes by SPS \[[@sfy008-B10]\]. It has therefore been suggested that enteral nutrition could be pretreated with SPS prior to administration, with removal of the potassium-rich resin precipitant prior to feeding, hopefully reducing the risk of the above-mentioned adverse effects while still optimizing nutrition.

Several prior studies confirm that pretreatment of enteral nutrition with SPS lowers the potassium content of feeds significantly \[[@sfy008-B10]\]. Other electrolyte disturbances are also reported, most notably a significant increase in feed sodium content (universal in all studies) \[[@sfy008-B10]\]. In addition, measured levels of calcium, magnesium and phosphate within the feed are all reported to be impacted by pretreatment with SPS, although there is less cross-study agreement on the severity and nature of the change. These studies are summarized in [Table 1](#sfy008-T1){ref-type="table"}. Importantly, all of these studies, with the exception of five cases observed by Bunchman *et al.* \[[@sfy008-B10]\] and a retrospective cohort study of 13 patients by Thompson *et al.* \[[@sfy008-B12]\], were conducted *in vitro*. This is therefore the second retrospective study to describe the clinical consequences of pretreating feeds with SPS *in vivo*, and although it demonstrated a similar electrolyte profile to Thompson *et al.*, had a longer follow-up period \[[@sfy008-B12]\]. Table 1.Summary of all published studies, in the English language, examining the effects of enteral feed pre-treatment with polystyrene sulfonateStudyEnteral nutritionType of SPSDose of SPS (g/mEqK)PretreatmentK changeNa changeCa changeMg changeOther changeOtherIndex article Palma *et al.* (USA) \[[@sfy008-B18]\]Not specifiedSPSInitially 0.5--1.0Shaken 1 min, fridge 30--60 min↓ 26%[^a^](#tblfn2){ref-type="table-fn"} (serum)↑4.1%[^a^](#tblfn2){ref-type="table-fn"} (serum)↔↔↑P[^a^](#tblfn2){ref-type="table-fn"}↔ Bic, ClReduced to 0.3--0.6(31.6% hypoK)(26.3% hyperNa)(21.1% hypoCa)Taylor *et al.* (USA) \[[@sfy008-B11]\]Suplena and Similac PM 60/40SPS suspension0.25, 0.5 and 1.0Shaken 60 s, fridge 30--60 minSuplena:Suplena:Suplena:Suplena: ↔Suplena:↑ pH[^a^](#tblfn2){ref-type="table-fn"}↓ 9, 6, 34[^a^](#tblfn2){ref-type="table-fn"}% (per dose)↑ 89[^a^](#tblfn2){ref-type="table-fn"}, 182[^a^](#tblfn2){ref-type="table-fn"}, 260[^a^](#tblfn2){ref-type="table-fn"}% (per dose)↓ 11, 17[^a^](#tblfn2){ref-type="table-fn"}, 38[^a^](#tblfn2){ref-type="table-fn"}% (per dose)Similac: ↓ 26[^a^](#tblfn2){ref-type="table-fn"}, 17, 3% (per dose)↓ Cu (3, 3, 11[^a^](#tblfn2){ref-type="table-fn"}%) ↓ Mn (3, 7[^a^](#tblfn2){ref-type="table-fn"}, 16[^a^](#tblfn2){ref-type="table-fn"}%) ↓ P (0, 2, 7[^a^](#tblfn2){ref-type="table-fn"}%)↑ Al (linear)(study also looked at pretreating with Renvela, and combined SPS and renvela)Similac:Similac:Similac:↓ 33[^a^](#tblfn2){ref-type="table-fn"}, 42[^a^](#tblfn2){ref-type="table-fn"}, 63[^a^](#tblfn2){ref-type="table-fn"}% (per dose)↑ 86[^a^](#tblfn2){ref-type="table-fn"}, 188[^a^](#tblfn2){ref-type="table-fn"}, 247[^a^](#tblfn2){ref-type="table-fn"}%↓ 8, 13, 29 ^a^% (per dose)↓ Zn (linear, 5, 10[^a^](#tblfn2){ref-type="table-fn"}, 20[^a^](#tblfn2){ref-type="table-fn"}%) (per dose) ↑ Fe (linear, 9[^a^](#tblfn2){ref-type="table-fn"}, 25[^a^](#tblfn2){ref-type="table-fn"}, 34\*%),↑ S (19, 45[^a^](#tblfn2){ref-type="table-fn"}, 41[^a^](#tblfn2){ref-type="table-fn"}%)Similac:↓ Cu (19[^a^](#tblfn2){ref-type="table-fn"},5, 14%)↑ Fe (linear, 13, 53[^a^](#tblfn2){ref-type="table-fn"}, 87[^a^](#tblfn2){ref-type="table-fn"}%)↔ P, S, ZnThompson *et al.* (USA) \[[@sfy008-B12]\]Expressed breast milk and Similac PM 60/40SPS (Kayexalate)0.4--1.5Shaken 2 min, fridge 60--120 min↓ 24%[^a^](#tblfn2){ref-type="table-fn"} (serum) (↓ 18--50% in pretreated formula)↑ 2% (serum) (not significant)↓ 7%[^a^](#tblfn2){ref-type="table-fn"}↔↓ 5% Creat[^a^](#tblfn2){ref-type="table-fn"}↔ Bic, BUN, Cl, PCameron *et al.* (Canada) \[[@sfy008-B13]\]Nestle Good StartBrand name SPS (Kayexalate) and generic SPS10, 20, 30 and 40 mLShaken 2 min, fridge for 1 h and 24 h↓ 53--88%↑ 324--494%No change 1/24 hNo change 1/24 hBonmati *et al.* (Spain) \[[@sfy008-B14]\]Osmolite HN, Nutrison Standard, Isosource StandardResinsodio (SPS) and resincalcio (CPS)---numbers not included15 and 30 g/LMixed 15 min, standing 48 h at 37°C↓ roughly 65--75% (per dose)↑ 147--191% (per dose) (range 127--215%)↓ roughly 67--76% (per dose)↓ roughly 65--72% (per dose)Rivard *et al.* (USA) \[[@sfy008-B15]\]Impact 1.5 (high protein)SPS (Kayexalate)0.5 or 1.0Mixed 20 min, stand 24 h↓ 25--36% (per dose)↑ 243--342% (per dose)↓13.7--13% (per dose)↔Modest ↑ P, Fe, ZnModest ↓ in proteinFassinger *et al.* (USA) \[[@sfy008-B16]\]Similac PM 60/40SPS and CPS (calcium resonium)1.0Mixed 20 min, fridge 50 min↓ 78%↑ 3.85-fold↔↔ Zn(12% CPS)(↓ by CPS)Bunchman *et al.* (USA) \[[@sfy008-B10]\]13 juices, milks and formulasGranular and sorbitol suspended1.0Shaken 1 min, fridge 30 min↓ 38--81%↑ 93--527%↓ 45--84%↓ 35--100%Starbuck (USA) \[[@sfy008-B17]\]MilkDowex and AG resinsVarious number of tablespoonsStirred, decanted after settling↓ roughly 80%↑ roughly 380%↓ 35--72%Slight ↓ pH and proteineffect plateauseffect linear[^1][^2]

The rates of clinical hypokalaemia (31.6%) and hypernatraemia (26.3%) described by Palma *et al.* \[[@sfy008-B18]\] mimic the *in vitro* findings on the potassium and sodium content of feeds following pretreatment with SPS \[[@sfy008-B10]\], although the degree of electrolyte disturbance is less marked. For example, clinical hypernatraemia developed following SPS pretreatment in only five cases (26.3%), despite the reported increase in *in vitro* studies of sodium feed content by 86--527% \[[@sfy008-B10], [@sfy008-B11], [@sfy008-B13]\]. Most *in vitro* studies also demonstrate a reduction in feed calcium content following pretreatment with SPS (range 8--84%) \[[@sfy008-B10], [@sfy008-B11], [@sfy008-B14], [@sfy008-B15], [@sfy008-B17]\], contributing to the reported incidence of episodic hypocalcaemia seen by Palma *et al.* \[[@sfy008-B18]\] in four cases (21.1%). The impact on ionized calcium, a more relevant *in vitro* measurement, remains unknown. The preparation and method of pretreatment of enteral nutrition with SPS had a similar methodology compared with other studies, so does not explain the *in vivo* and *in vitro* differences. Independent of potassium, sodium and calcium, Palma *et al.* \[[@sfy008-B18]\] found no significant difference in bicarbonate or chloride levels, which is consistent with the previous *in vivo* study by Thompson *et al.* \[[@sfy008-B12]\]. However, as demonstrated in other studies (see [Table 1](#sfy008-T1){ref-type="table"}) \[[@sfy008-B11], [@sfy008-B15], [@sfy008-B16]\], due to the non-specific binding nature of SPS, there may be significant, yet inconsistent effects on other essential trace elements such as zinc, copper and manganese. Although not as acutely life-threatening as fluctuations in potassium and calcium, these are essential for adequate growth and maintenance of health \[[@sfy008-B19]\].

Children with CKD are a heterogeneous population, differing in age, size, associated comorbidities, concomitant medications that may be present and, most importantly, aetiology. Congenital anomalies of the kidney and urinary tract are the most common cause of CKD in infants and younger children, while glomerular disorders are a more common aetiology in older children, particularly \>12 years of age \[[@sfy008-B2]\]. The clinical implications of increased sodium content in feed following pretreatment with SPS may be more profound depending on the underlying primary renal disease. For example, children with a salt-wasting nephropathy may be less vulnerable to higher sodium loads than others.

The most informative aspect of this report is the adverse effect profile. Although common practice in some paediatric nephrology units and first described some 45 years ago, the authors correctly identify the paucity of evidence to support the practice of pretreatment and are to be commended for their efforts in compiling this case series to highlight the adverse effect profile, particularly the potentially serious complications that can arise. They report that 47.4% of patients required a dose adjustment after the first week of treatment and half of courses were discontinued due to adverse effects. Importantly, in 2 of the 14 patients, these effects were potentially life-threatening events. The gastrointestinal disturbances and hypocalcaemia described in the first case are similar to case reports elsewhere: Kakajiwala *et al.* \[[@sfy008-B20]\] describe two cases of hypocalcaemia and metabolic alkalosis attributed to the use of SPS, where one child was receiving pretreated formula. In the second case of potentially life-threatening adverse events described by Palma *et al.* \[[@sfy008-B18]\], although causation cannot be certain due to other comorbidities, clinicians must be aware that the addition of SPS to feeds is not a benign or risk-free intervention. Furthermore, these events occurred with correct preparation and pretreatment in a hospital environment. The risk profile of continuing SPS pretreatment in the community setting has not been evaluated. Despite this, hyperkalaemia also carries significant risks and any efforts to improve the management of this challenging aspect of CKD are to be lauded.

Palma *et al.* \[[@sfy008-B18]\] have described their centre's experience of pretreatment of feeds with SPS, providing a cautionary tale to all paediatric nephrologists---simplifying the administration of a medication through pretreatment is not necessarily beneficial. The adverse effect profile must be considered in all patients prior to commencing pretreatment. Where it is felt to be essential, we heartily agree with the authors' conclusions that close monitoring of electrolytes is mandatory. Much more work is needed to identify those patient cohorts for which this can indeed be considered a safe and effective intervention.
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[^1]: CPS, calcium polystyrene sulphonate; ↑, increased; ↓, decreased; ↔, unchanged; K, potassium; Na, sodium; Ca, calcium; Mg, magnesium; Bic, bicarbonate; Cl, chloride; Cu, copper; Fe, iron; Zn, zinc; Mn, manganese; P, phosphorus; S, sulphur; Al, aluminium; BUN, blood urea nitrogen; Creat, creatinine.

[^2]: Statistically significant change if commented on.
